Department of Paediatric Neurology, Medical University in Lublin, Lublin, Poland.
Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
Adv Med Sci. 2014 Mar;59(1):34-8. doi: 10.1016/j.advms.2013.07.002. Epub 2014 Mar 16.
This study is a pilot evaluation of the quality of life (QoL) in Polish patients with multiple sclerosis (MS).
MATERIAL/METHODS: Data from 21 centers in Poland were collected from May 2008 to January 2009. QoL was assessed using the questionnaire Euro Quality of Life (EQ-5D), with Polish population norms. Demographic profile of patients, duration/form/relapsing activity of the disease, disability and comorbidity were also analyzed.
Data from 3521 patients (F/M ratio 2.4:1) were collected. The average EQ-5D index was 0.8 ± 0.27 and the mean score in a visual analog scale (EQ-VAS) was 65.6 ± 21.5. There was a highly significant positive correlation between both indices (r=0.7334, p<0.0001). The mean patient age was 40.7 years (11.2-92.3 years) and disease duration was 10.3 ± 8.8 years (0.04-53 years). 74.2% of subjects had relapsing-remitting form of MS, while 17.2% were classified as secondary progressive and 8.6% as primary progressive. In the group of relapsing-remitting MS subjects there were 2.5% patients with "benign MS". The average degree of disability on EDSS scale was 3.6 ± 2.2, while disability ≥6 was observed in 20.3% of patients. Most patients did not have other diseases besides MS.
This is the first large study of QoL in patients with MS in Poland (approximately 18% of all patients). Our results confirm a reduction in QoL compared with the general population. Further studies are indicated to identify the modifiable risk factors (e.g. type of treatment) that may affect QoL.
本研究旨在评估波兰多发性硬化症(MS)患者的生活质量(QoL)。
材料/方法:2008 年 5 月至 2009 年 1 月,从波兰的 21 个中心收集数据。使用问卷调查欧洲生活质量(EQ-5D)评估 QoL,并采用波兰人群的正常值。还分析了患者的人口统计学特征、疾病的持续时间/形式/复发活动、残疾和合并症。
共收集了 3521 名患者(男女比例 2.4:1)的数据。平均 EQ-5D 指数为 0.8 ± 0.27,视觉模拟量表(EQ-VAS)的平均得分为 65.6 ± 21.5。这两个指数之间存在高度显著的正相关(r=0.7334,p<0.0001)。患者平均年龄为 40.7 岁(11.2-92.3 岁),疾病持续时间为 10.3 ± 8.8 年(0.04-53 年)。74.2%的患者为复发缓解型 MS,17.2%为继发进展型,8.6%为原发进展型。在复发缓解型 MS 患者中,有 2.5%的患者为“良性 MS”。EDSS 量表上的平均残疾程度为 3.6 ± 2.2,而残疾≥6 的患者占 20.3%。大多数患者除 MS 外没有其他疾病。
这是波兰首次对多发性硬化症患者进行 QoL 的大型研究(约占所有患者的 18%)。我们的结果证实,与普通人群相比,QoL 下降。需要进一步研究确定可能影响 QoL 的可改变风险因素(例如治疗类型)。